Chronic Rhinosinusitis Clinical Trial
Official title:
Oral Versus Topical Antibiotic Therapy for Treatment of Chronic Rhinosinusitis Exacerbations
Verified date | March 2021 |
Source | University of Rochester |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to treat patients with a diagnosis of chronic rhinosinusitis (CRS) and a history of bilateral endoscopic sinus surgery during times of worsening symptoms and signs of acute infection on nasal endoscopy with one of two treatments: (1) oral antibiotics and twice daily intranasal saline irrigations or (2) oral placebo and twice daily intranasal antibiotic irrigations. The two treatments will be compared to see if there is any difference in patient outcomes. This will help guide treatment strategies for patients with CRS in the future.
Status | Completed |
Enrollment | 33 |
Est. completion date | December 31, 2020 |
Est. primary completion date | September 11, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Adults (age = 18). 2. Diagnosis of CRS. 3. Worsening sinonasal symptoms. 4. Previous bilateral endoscopic sinus surgery (ESS) (including maxillary antrostomy and anterior ethmoidectomy). 5. English speaking. 6. Open sinuses (open middle meatus bilaterally; determined on endoscopy). 7. Positive sinonasal culture (1+ or greater) with sensitivity to one of the pre-chosen antibiotic regimens. Exclusion Criteria: 1. Patients < 18 years of age. 2. Treatment with systemic or topical antibiotics within the last 1 month. 3. Pregnant women. 4. Non-English speaking persons. 5. Systemically ill at initial visit necessitating treatment prior to culture data. 6. Allergies to chosen susceptible antibiotics. 7. Sinonasal culture with less than 1+ growth. 8. Multiple organisms grown on culture that are not sensitive to a single antibiotic. 9. Patients with ciliary function disorders (cystic fibrosis, Kartagener's syndrome, ciliary dyskinesia). 10. Patients with immunodeficiencies. |
Country | Name | City | State |
---|---|---|---|
United States | University of Rochester Department of Otolaryngology Head and Neck Surgery | Rochester | New York |
Lead Sponsor | Collaborator |
---|---|
University of Rochester |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Rhinosinusitis Disability Index (RSDI) Score | The Rhinosinusitis Disability Index is a 30-item questionnaire completed by the patient or subject. Each item has a value of zero to four, a higher score indicates a self-perception of worse symptoms. The minimum score is zero and the maximum score is 120.
The difference score here is the post-treatment score minus the pre-treatment score, with lower meaning more improvement |
Baseline and 14 days after treatment | |
Secondary | Change in Sino-nasal Outcome Test (SNOT-22) Score | The Sino-nasal outcome test is a 22-item questionnaire completed by the patient or subject. Each item has a value of zero to five, a higher score indicates a self-perception of worse symptoms. The minimum score is zero and the maximum score is 110.
The difference score here is the post-treatment score minus the pre-treatment score, with lower meaning more improvement |
Baseline and 14 days after treatment | |
Secondary | Change in Bilateral Endoscopy Findings Using POSE Score | The Perioperative Sinus Endoscopy (POSE) instrument is a specific tool to endoscopically assess the sinus cavities of patients who have undergone endoscopic sinus surgery.
Each POSE score has a minimum of 0 and a maximum of 16, with a higher score indicating a worse outcome. Here, the Left and Right POSE scores are summed and the difference between baseline and the 14 day after treatment is reported. The change in bilateral POSE score can in principle be -32 to +32, with increased scores indicating worse outcome and negative scores indicating improvement over the treatment period. |
Baseline and 14 days after treatment | |
Secondary | Number of Participants With Post-treatment Culture Negativity | Post-treatment culture negativity, defined as less than 1+ growth of organisms. A subject is counted '1' if both nares are free of bacterial growth, and '0' if growth is 1+ of more | 14 days after treatment | |
Secondary | Mean Change in the Total Bacterial Community | The bacterial community was determined using a 16S rRNA quantitative PCR processed using Quantitative Insights into Microbial Ecology (QIIME) software, version 1.8 to yield the number of operational taxonomic units in each subject sample. The count has a minimum of zero with an increasing score indicating a larger number of distinct bacterial species. | Baseline and 14 days after treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04131686 -
NAC Inhalation in the Treatment Of Symptomatic acuTe rhinosinUSitis
|
||
Completed |
NCT02692794 -
Large Scale Cerebral Oximetry During Sinus Endoscopy
|
N/A | |
Completed |
NCT01254916 -
The Sinonasal Outcome Test - 22, Validated for Danish Patients
|
N/A | |
Completed |
NCT03614923 -
Etokimab in Adults With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
|
Phase 2 | |
Completed |
NCT03781804 -
Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis With or Without the Presence of Nasal Polyps
|
Phase 3 | |
Completed |
NCT01198912 -
Influence of Oral Doxycycline on Wound Healing After Endonasal Endoscopic Sinus Surgery for Chronic Rhinosinusitis With and Without Nasal Polyposis: a Double-blind Randomized Placebo-controlled Trial
|
Phase 2 | |
Active, not recruiting |
NCT06457100 -
Esmolol Versus Lidocaine on the Quality of Postoperative Recovery in Patients Undergoing Functional Endoscopic Sinus Surgery
|
Phase 1/Phase 2 | |
Completed |
NCT03280537 -
A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitus With Nasal Polyps
|
Phase 3 | |
Completed |
NCT02307825 -
Azithromycin for Patients With Chronic Rhinosinusitis Failing Medical and Surgical Therapy
|
Phase 4 | |
Terminated |
NCT02285283 -
Itraconazole for Fungal Sensitive Chronic Rhinosinusitis With Nasal Polyps
|
Phase 2/Phase 3 | |
Completed |
NCT02218307 -
The Use of Antibiotic Sinonasal Rinse After Sinus Surgery
|
Phase 4 | |
Recruiting |
NCT01024075 -
Effect of Sinufoam-Dexamethasone Mixture on Post Endoscopic Sinus Surgery Outcomes
|
Phase 4 | |
Completed |
NCT01002313 -
Effect of Prednisone onTregs and TH17
|
Phase 1 | |
Completed |
NCT00396162 -
Use of Probiotics as Adjunctive Treatment for Chronic Rhinosinusitis
|
Phase 4 | |
Completed |
NCT03280550 -
A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps
|
Phase 3 | |
Recruiting |
NCT05935683 -
Rhinosinusitis Italian Network: the Italian Registry for Severe, Uncontrolled Chronic Rhinosinusitis
|
||
Completed |
NCT03478930 -
An Extension Study of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps
|
Phase 3 | |
Completed |
NCT01943370 -
Early Saline Irrigation to Decrease Post-operative Endoscopic Debridement
|
N/A | |
Completed |
NCT02154555 -
A Randomized Controlled Trial Evaluating Postoperative Debridement Following Endoscopic Sinus Surgery
|
N/A | |
Completed |
NCT01778465 -
Effect of Dietary Salicylate in Aspirin Exacerbated Respiratory Disease
|
N/A |